4BIO Capital is a London-based venture capital firm focused solely on advanced therapies — including cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome — addressing high unmet medical and social needs. The firm invests in and incubates early-stage companies developing emerging treatments.
45% of their portfolio is in Biotech & Life Sciences. Deal activity increased 200% year-over-year (3 deals in the last 12 months). Their most common stage is series-a (59% of deals). Average disclosed round size is $65.2M (across 14 rounds with reported amounts).
Portfolio
19
Fund Size
—
Top Stage
Series A
Last 12 Mo
4
Team
SHIKIN GANI
EXECUTIVE ASSISTANT
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
22 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Cytospire Therapeutics | Series A | — | May 2026 |
| Cytospire Therapeutics | Series A | $61M | Jan 2026 |
 Trogenix | Series A | — | Oct 2025 |
| TTrogenix | Series A | $70M | Oct 2025 |
 March Biosciences | Series A | $28.4M | Oct 2024 |
| VVolnay | Series A | $28.4M | Jan 2024 |
 Ray Therapeutics | Series A | $100M | May 2023 |
| AAscend Gene & Cell Therapies | Series A | $132.5M | May 2023 |
| AAscend Advanced Therapies | Series A | $132.5M | Mar 2023 |
 Entact Bio | Series A | $81M | Dec 2022 |
 SparingVision | Series B | — | Sep 2022 |
 Araris Biotech | Unknown | $24M | Jan 2022 |
| CCarisma Therapeutics, Inc. | Series B | — | Mar 2021 |
| Araris Biotech | Seed | — | Oct 2020 |
| AAraris | Seed | — | Oct 2020 |
| RRedPin Therapeutics | Series A | $15.5M | Mar 2020 |
| SparingVision | Unknown | — | Jan 2020 |
 Actithera | Series A | $75.5M | — |
| CCode Bio | Series A | $75M | — |
| SSparing Vision | Series B | — | — |
 Luca Science | Series B | $30.3M | — |
 CARISMA | Series B | $59M | — |
Top Co-Investors
Abingworth LLP5 shared
UPMC Enterprises4 shared
Alexandria Venture Investments3 shared
Deerfield3 shared
MRL Ventures Fund3 shared
Bpifrance3 shared
Ysios Capital3 shared
Jeito Capital3 shared
Vi Partners3 shared
Redalpine3 shared
Pureos Bioventures3 shared
TMC Venture Fund2 shared
Cancer Focus Fund2 shared
Mission BioCapital2 shared
Cancer Research Horizons2 shared
IQ Capital2 shared
Brain Tumor Investment Fund2 shared
Calculus Capital2 shared
LongeVC2 shared
Eli Lilly and Company2 shared
Last updated: 8 September 2026